• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Definium Therapeutics Inc.

    6/25/26 4:10:23 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $DFTX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001331843
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    DEFINIUM THERAPEUTICS, INC.
    SEC File Number
    001-40360
    Address of Issuer
    ONE WORLD TRADE CENTER
    SUITE 8500
    NEW YORK
    NEW YORK
    10007
    Phone
    212-220-6633
    Name of Person for Whose Account the Securities are To Be Sold
    MARK SULLIVAN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    13008548027.0410906678306/25/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/25/2026Restricted Stock Vesting Under a Registered PlanIssuerCheckbox not checked1300806/25/2026Services Rendered

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    MARK SULLIVAN
    ONE WORLD TRADE CENTER
    SUITE 8500
    NEW YORK � NY � 10007
    Common03/25/202610702197665.94

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/25/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Mark Sullivan

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $DFTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DFTX

    DatePrice TargetRatingAnalyst
    6/23/2026$38.00 → $50.00Buy
    Needham
    4/17/2026$30.00Buy
    Stifel
    4/10/2026$49.00Overweight
    Piper Sandler
    2/24/2026$25.00Outperform
    Wolfe Research
    1/30/2026$30.00Buy
    Jefferies
    More analyst ratings

    $DFTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Definium Therapeutics with a new price target

    Needham reiterated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $50.00 from $38.00 previously

    6/23/26 7:52:49 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Stifel initiated coverage on Definium Therapeutics with a new price target

    Stifel initiated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $30.00

    4/17/26 8:10:40 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Piper Sandler initiated coverage on Definium Therapeutics with a new price target

    Piper Sandler initiated coverage of Definium Therapeutics with a rating of Overweight and set a new price target of $49.00

    4/10/26 8:31:32 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    SEC Filings

    View All

    SEC Form 144 filed by Definium Therapeutics Inc.

    144 - Definium Therapeutics, Inc. (0001813814) (Subject)

    6/25/26 4:10:23 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 144 filed by Definium Therapeutics Inc.

    144 - Definium Therapeutics, Inc. (0001813814) (Subject)

    6/25/26 4:09:36 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 144 filed by Definium Therapeutics Inc.

    144 - Definium Therapeutics, Inc. (0001813814) (Subject)

    6/25/26 4:08:06 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    Definium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the closing of its previously announced underwritten public offering of 23,676,471 common shares, without par value, which includes the exercise in full by the underwriters of their option to purchase 3,088,235 additional common shares, at a public offering price of $34.00 per common share. All of the shares were offered by Definium. The gross proceeds from this offering were $805 million, before deducting underwriting discounts, com

    6/25/26 4:15:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

    Definium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the pricing of an underwritten public offering of 20,588,236 common shares, without par value, at a public offering price of $34.00 per common share. The gross proceeds to Definium from the offering, before deducting underwriting discounts, commissions, and other offering-related expenses, are expected to be approximately $700 million. In addition, Definium has granted the underwriters an option for a period of 30 days to purchase up

    6/23/26 9:57:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Definium Therapeutics, Inc. Announces Proposed Public Offering

    Definium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it intends to offer and sell, subject to market conditions, $500 million of its common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. In addition, Definium intends to grant the underwriters an option for a period of 30 days to purchase up to $75 million of its common shares at the public offering price, less underwriting discounts and commissions. All of the co

    6/22/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 24% to 513,317 units (SEC Form 4)

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    6/22/26 9:45:03 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 50% to 1,127,454 units (SEC Form 4)

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    6/22/26 9:45:05 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 23% to 333,579 units (SEC Form 4)

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    6/22/26 9:45:04 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Leadership Updates

    Live Leadership Updates

    View All

    Definium Therapeutics Appoints Roger Adsett to Board of Directors

    Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium's next phase of growth Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. "We are thrilled to welcome Roger to our Board of Directors," said Rob Barrow, Chief Executive Officer of Definium Therapeutics. "Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact. At Insmed, he's led the development of world-class commercial and operation

    1/29/26 7:00:00 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Financials

    Live finance-specific insights

    View All

    Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

    Three Phase 3 topline data readouts for DT120 ODT expected in the coming months DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in 2027 $373.4 million in cash, cash equivalents, and investments as of March 31, 2026, expected to fund operations into 2028 Conference call scheduled today at 4:30 p.m. EDT Definium Therapeutics, Inc. ("Definium" or the "Company") (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended March 31, 2026, and recent highlights. "After an

    5/7/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

    Definium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, May 7, 2026 to report financial results for the first quarter ended March 31, 2026, and discuss recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the Definium Therapeutics website, ir.definiumtx.com, a

    4/30/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

    Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026 Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026 $411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028 Conference call scheduled today at 4:30 p.m. EST Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorder

    2/26/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care